Search results for " Combination"

showing 10 items of 923 documents

A note on k-generalized projections

2007

Abstract In this note, we investigate characterizations for k -generalized projections (i.e., A k  =  A ∗ ) on Hilbert spaces. The obtained results generalize those for generalized projections on Hilbert spaces in [Hong-Ke Du, Yuan Li, The spectral characterization of generalized projections, Linear Algebra Appl. 400 (2005) 313–318] and those for matrices in [J. Benitez, N. Thome, Characterizations and linear combinations of k -generalized projectors, Linear Algebra Appl. 410 (2005) 150–159].

Pure mathematicsNumerical AnalysisAlgebra and Number TheoryNormal matricesHilbert spaceCharacterization (mathematics)Matrius (Matemàtica)Normal matrixAlgebrasymbols.namesakeLinear algebrasymbolsDiscrete Mathematics and CombinatoricsSpectral projectionGeometry and TopologyÀlgebra linealLinear combinationProjectionst-Potent matricesMathematicsLinear Algebra and its Applications
researchProduct

Occurrence of illicit drugs in two wastewater treatment plants in the South of Italy

2017

In this study the occurrence and the behavior of illicit drugs and their metabolites have been investigated for two wastewater treatment plants (WWTPs) (namely, WWTP-1 and WWTP-2) located in Sicily (island of Italy). Samples were analyzed for methamphetamine, cocaine (COC), 3,4-methylenedioxymethamphetamine (MDMA), methadone (METH), 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), 3,4-methylenedioxy amphetamine (MDA); 3,4-methylenedioxy ethylamphetamine (MDEA), 11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) and Benzoylecgonine (BEG). The BEG, COC, MOR and THC-COOH were found at the highest concentration in both WWTPs. The Wastewater-based epidemiology calculation for BEG, COC…

PyrrolidinesHealth Toxicology and Mutagenesis0208 environmental biotechnology02 engineering and technologyWastewater010501 environmental sciencesSettore MED/42 - Igiene Generale E ApplicataWaste Disposal Fluid01 natural sciencesMethamphetamineIllicit drugchemistry.chemical_compoundCocaineSettore BIO/10 - BiochimicaCannabidiolWater treatmentDronabinolSicilyDrug behavioreducation.field_of_studybiologyTraditional medicineChemistry (all)MDMAGeneral MedicineMethamphetaminePollutionContaminants of emerging concernSubstance Abuse DetectionDrug CombinationsBenzoylecgoninemedicine.drugEnvironmental EngineeringPopulationmedicineHumansEnvironmental Chemistryeducation0105 earth and related environmental sciencesSettore ICAR/03 - Ingegneria Sanitaria-AmbientaleIllicit Drugsbusiness.industryAmphetaminesCodeinePublic Health Environmental and Occupational HealthGeneral Chemistrybiology.organism_classificationEthylamphetamine020801 environmental engineeringAmphetaminechemistryCannabisbusinessWater Pollutants ChemicalMethadoneChemosphere
researchProduct

The rate of photon production in the quark-gluon plasma from lattice QCD

2020

We calculate the thermal rate of real-photon production in the quark-gluon plasma at a temperature of $T=254$ MeV using lattice QCD. The calculation is based on the difference between the spatially transverse and longitudinal parts of the polarization tensor, which has the advantage of falling off rapidly at large frequencies. We obtain this linear combination in the time-momentum representation from lattice QCD with two flavors of quarks in the continuum limit with a precision of about two parts per mille. Applying a theoretically motivated fit ansatz for the associated spectral function, we obtain values for the photon rate that are in line with QCD weak-coupling calculations; for photon …

QuarkParticle physicsPhotonNuclear Theorynucl-thHigh Energy Physics::LatticePhoton Production RateFOS: Physical scienceshep-latLattice QCD7. Clean energy01 natural sciencesNuclear Theory (nucl-th)High Energy Physics - LatticeHigh Energy Physics - Phenomenology (hep-ph)0103 physical sciences010306 general physicsLinear combinationAnsatzParticle Physics - PhenomenologyQuantum chromodynamicsPhysics010308 nuclear & particles physicsHigh Energy Physics - Lattice (hep-lat)High Energy Physics::Phenomenologyhep-phParticle Physics - LatticeLattice QCDPolarization (waves)3. Good healthHigh Energy Physics - PhenomenologyNuclear Physics - TheoryQuark–gluon plasmaQuark-Gluon PlasmaHigh Energy Physics::Experiment
researchProduct

Coloring Linear Algebra

2016

[EN] We present an example of how we can introduce basic concepts on Linear Algebra in a first course of an Engineering School. We use the RGB pattern color which allows us to decompose a color into three primary colors (namely, red, green, blue). By using this model we give a natural connexion between the additivity of the color decomposition and the notions on linear algebra (as vector space, linear combination and convex linear span of vectors). To visualize these connexions we use Geogebra.

RGB pattern colorLinear AlgebraMathematical modellingLinear combinationÁlgebra lineal combinación lineal modelización matemática modelo de color RGBModelización matemáticaÁlgebra linealModelo de color RGBlcsh:L7-991lcsh:Education (General)Combinación linealModelling in Science Education and Learning
researchProduct

Strict blood-pressure control and progression of renal failure in children

2009

PubMedID: 19846849 BACKGROUND: Although inhibition of the renin-angiotensin system delays the progression of renal failure in adults with chronic kidney disease, the blood-pressure target for optimal renal protection is controversial. We assessed the long-term renoprotective effect of intensified blood-pressure control among children who were receiving a fixed high dose of an angiotensin-converting- enzyme (ACE) inhibitor. METHODS: After a 6-month run-in period, 385 children, 3 to 18 years of age, with chronic kidney disease (glomerular filtration rate of 15 to 80 ml per minute per 1.73 m2 of body-surface area) received ramipril at a dose of 6 mg per square meter of bodysurface area per day…

RamiprilMaleMean arterial pressuremedicine.medical_specialtyAdolescentUrologyRenal functionAngiotensin-Converting Enzyme InhibitorsBlood PressureKaplan-Meier EstimateRamiprilmedicineClinical endpointHumansRenal Insufficiency ChronicChildDEPARTMENTSAntihypertensive AgentsProteinuriabusiness.industryHazard ratioGeneral MedicineBlood Pressure Monitoring Ambulatorymedicine.diseaseSurgeryProteinuriaBlood pressureChild PreschoolCreatinineHypertensionDisease ProgressionKidney Failure ChronicDrug Therapy CombinationFemalemedicine.symptombusinessKidney diseasemedicine.drugGlomerular Filtration Rate
researchProduct

Ambulatory Blood Pressure Values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET)

2012

In the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial, telmisartan (T; 80 mg daily) and ramipril (R; 10 mg daily) caused similar clinic blood pressure (BP) reductions, with a similar incidence of cardiovascular and renal events. The R+T combination lowered clinic BP somewhat more with no further cardiovascular or renal protection. The aim of this substudy was to see whether these clinic BP changes reflected the changes of 24-hour BP, a BP with a better prognostic value. In 422 patients in whom 24-hour BP monitoring was performed either before or after 6 to 24 months of treatment, demographic and clinical characteristics were similar in the 3 treated groups.…

RamiprilMalemedicine.medical_specialtyAmbulatory blood pressureDiastoleAngiotensin-Converting Enzyme InhibitorsBlood PressureBenzoateslaw.inventionRandomized controlled trialRamiprillawInternal medicineInternal MedicinemedicineHumansLongitudinal StudiesTelmisartanAntihypertensive AgentsAgedbusiness.industryambulatory blood pressure antihypertensive treatment high cardiovascular risk angiotensin-converting enzyme inhibitors angiotensin receptor blockersMED/11 - MALATTIE DELL'APPARATO CARDIOVASCOLAREBlood Pressure Monitoring AmbulatoryMiddle AgedEndocrinologyBlood pressureTreatment OutcomeTarget drugAmbulatoryHypertensionCardiologyBenzimidazolesDrug Therapy CombinationFemaleTelmisartanbusinessmedicine.drug
researchProduct

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

2019

Abstract Aims Studies have shown a non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and outcomes, with increased risk observed at both low and high blood pressure (BP) levels. We hypothesized that the BP-risk association is different in individuals with and without diabetes at high cardiovascular risk. Methods and results We identified patients with (N = 11 487) or without diabetes (N = 19 450), from 30 937 patients, from 133 centres in 44 countries with a median follow-up of 56 months in the ONTARGET/TRANSCEND studies. Patients had a prior history of stroke, myocardial infarction (MI), peripheral artery disease, or were high-risk diabetics. P…

Ramiprilmedicine.medical_specialtyhypertensionSystoleAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRamiprilDiastoleRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumanshigh cardiovascular riskTelmisartan030212 general & internal medicineMyocardial infarctionStrokeRetrospective StudiesHeart Failurediabetesbusiness.industryHazard ratioblood pressureBlood Pressure Determinationmedicine.diseasestrokeHospitalizationmyocardial infarctionBlood pressureCardiovascular DiseasesCase-Control StudiesHeart failureCardiologyDrug Therapy CombinationTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugEuropean Heart Journal
researchProduct

Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency

2014

a b s t r a c t Background: Data on the efficacy of Peg-interferon/ribavirin therapy for chronic hepatitis C are mostly derived from treatment of selected patients enrolled in clinical trials. This study aimed to assess the effectiveness of Peg-interferon/ribavirin therapy in “real world” chronic hepatitis C patients in Italy. Methods: Independent observational multicentre study including consecutive patients receiving Peginterferon/ribavirin in the 18 months before (retrospective phase) and after (prospective phase) the start of the study. Results: 4176 patients were eligible. The final study population consisted of 2051 patients in the retrospective and 2073 in the prospective phase. Sust…

RegistrieMaleCirrhosismedicine.disease_causePolyethylene GlycolGastroenterologyPolyethylene Glycolschemistry.chemical_compoundHepatitis VirusesHepatitis ViruseProspective StudiesViralRegistriesChronicProspective cohort studyDrug CarrierDrug CarriersSettore MED/12 - GastroenterologiaMedicine (all)GastroenterologyRecombinant ProteinMiddle AgedHepatitis CRecombinant ProteinsTreatment OutcomeItalyCombinationRNA ViralPopulation studyDrug Therapy CombinationFemaleHumanmedicine.medical_specialtyGenotypeHepatitis C virusAlpha interferonRibavirin; Sustained virological response (SVR); TreatmentAntiviral AgentsFollow-Up StudieRibavirin; Sustained virological response (SVR); Treatment; Hepatology; GastroenterologyDrug TherapyInternal medicineRibavirinmedicineHumansAntiviral AgentHepatologybusiness.industryRibavirinInterferon-alphaHCV therapyHepatitis C ChronicHepatologymedicine.diseaseClinical trialTreatmentProspective StudiechemistryImmunologyRNARibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; RegistriesbusinessRibavirin; Sustained virological response (SVR); Treatment; Antiviral Agents; Drug Carriers; Drug Therapy Combination; Female; Follow-Up Studies; Genotype; Hepatitis C Chronic; Hepatitis Viruses; Humans; Interferon-alpha; Italy; Male; Middle Aged; Polyethylene Glycols; Prospective Studies; RNA Viral; Recombinant Proteins; Ribavirin; Treatment Outcome; Registries; Gastroenterology; Hepatology; Medicine (all)Follow-Up StudiesSustained virological response (SVR)
researchProduct

Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register

2014

Abstract Introduction Rituximab (RTX) is a monoclonal anti-CD20 antibody approved for the treatment of rheumatoid arthritis (RA) in association with methotrexate (MTX). Objectives To evaluate the efficacy and safety of RTX–MTX combination therapy compared with RTX alone in the treatment of RA. Methods We analyzed data from a prospective cohort study, the Italian biologic register GISEA, to investigate the efficacy and safety of rituximab. Moreover, the adverse events (AE) and the causes of discontinuation therapy were analyzed. Results We identified 338 RA patients, 162 treated with RTX and 176 with RTX–MTX. After 52 and 104 weeks of therapy the disease activity score in 28 joints and the H…

RegistrieMaleanti-CD20 rituximab; rheumatoid arthritis; GISEArheumatoid arthritisSettore MED/16 - REUMATOLOGIAAnti-CD20Arthritis RheumatoidAntibodies Monoclonal Murine-DerivedRheumatoidMonoclonalRegistriesProspective cohort studyGISEAAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Treatment Outcome; RegistriesAntirheumatic AgentAntibodies MonoclonalMiddle AgedTreatment OutcomeRituximab rheumatoid arthritisAntirheumatic AgentsRheumatoid arthritisCombinationMonoclonalDrug Therapy CombinationFemaleRituximabRituximabHumanmedicine.drugmusculoskeletal diseasesAdultMurine-Derivedmedicine.medical_specialtyCombination therapyAntibodiesNOAnti-CD20; Methotrexate; Rheumatoid arthritis; RituximabDrug TherapyRheumatologyanti-CD20 rituximabInternal medicinemedicineHumansRheumatoid arthritisAdverse effectRheumatoid arthritiAnti-CD20; Methotrexate; Rheumatoid arthritis; Rituximab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Murine-Derived; Antirheumatic Agents; Arthritis Rheumatoid; Drug Therapy Combination; Female; Humans; Male; Methotrexate; Middle Aged; Rituximab; Treatment Outcome; Registries; RheumatologyAgedbusiness.industryArthritismedicine.diseaseSurgeryDiscontinuationMethotrexateMethotrexatebusinessJoint Bone Spine
researchProduct

Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

2023

Background: Immuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC). Objective: The ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients. Patients and methods: Patients aged ≥ 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB). Results: A total of 729 patie…

Renal Cell CarcinomaImmunotherapyImmuno-oncology Combinations
researchProduct